Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
PD1 and PARP for Maintenance Therapy in NSLLC

PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1 plus maintenance PARP for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: respect

squamous cell carcinoma
fdg pet
x-rays
measurable disease
pleural effusion
  • 0 views
  • 06 Jun, 2022
  • 1 location
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

pemetrexed, cisplatin in approximately 228 TKI(tyrosine kinase inhibitor) pre treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR mutation or ALK translocation.

lung carcinoma
serum bilirubin level
carboplatin
paclitaxel
osimertinib
  • 0 views
  • 08 Jan, 2022
  • 1 location
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

NSCLC and 9.2 months in squamous NSCLC . In this setting the programmed death 1/ligand 1 (PD-1/-L1) were targeted with nivolumab (IgG4) in advanced squamous and nonsquamous NSCLC leading to an increase

lung carcinoma
pembrolizumab
carboplatin
paclitaxel
nivolumab
  • 3 views
  • 12 Aug, 2022
  • 26 locations
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

breast cancer (TNBC), non-TNBC HER2-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will

estrogen receptor
progesterone receptor
lung carcinoma
pancreatic cancers
her2/neu-negative breast cancer
  • 14 views
  • 15 Jul, 2022
  • 11 locations
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not received prior systemic therapy in the metastatic or locally advanced setting. Eligible subjects must have measurable

measurable disease
systemic therapy
atezolizumab
  • 0 views
  • 27 May, 2022
  • 11 locations
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Dose Expansion, U3-1402 will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations

lung carcinoma
afatinib
osimertinib
growth factor
epidermal growth factor
  • 38 views
  • 29 Jul, 2022
  • 7 locations
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

The "PACIFIC" trial confirmed that the consolidation therapy with durvalumab in patients with stage III, locally advanced, unresectable NSCLC that had not progressed after definitive platinum-based chemoradiation therapy improved the progression-free survival (PFS) by about 17 months. However, in PACIFIC, no significant differences between durvalumab and placebo were observed in …

  • 0 views
  • 12 Jul, 2022
  • 2 locations
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR)

found in only the half of the non-squamous NSCLC . More recently, immune check point inhibitors (ICI), firstly targeting PD-(L)1, became available and demonstrate an overall survival advantage over

lung carcinoma
pembrolizumab
serum bilirubin level
nivolumab
growth factor
  • 0 views
  • 28 Feb, 2022
  • 1 location
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

This is a phase 2 study of a drug called crizotinib in people with metastatic (the cancer has spread to other parts of the body) non-small cell lung cancer with a mutation (change) in genes called ROS1 or MET. The purpose of this study is to look at how effective …

crizotinib
squamous non-small cell lung cancer
measurable disease
ROS1
cancer
  • 0 views
  • 18 Dec, 2021
  • 1 location
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung

pd-l1
brain metastases
chronic hepatitis b
HIV Infection
paclitaxel
  • 25 views
  • 08 Aug, 2022
  • 439 locations